Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 84.90
+2.30 (2.78%)
Apr 29, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change (1Y)
1,843
Growth (1Y)
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
143.33B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| WuXi Biologics | 13,252 |
| Akeso | 3,761 |
| Sichuan Kelun-Biotech Biopharmaceutical | 2,045 |
| Sino Biopharmaceutical | 21,435 |
| BeOne Medicines AG | 12,000 |
| RemeGen | 3,048 |
| 3SBio | 6,109 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
Innovent Biologics News
- 7 days ago - Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting - PRNewsWire
- 19 days ago - Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases - PRNewsWire
- 4 weeks ago - Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema - PRNewsWire
- 4 weeks ago - Innovent Announces 2025 Annual Results and Business Updates - PRNewsWire
- 5 weeks ago - Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study - PRNewsWire
- 2 months ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 2 months ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 2 months ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters